Tatva Chintan – Major Trendline #Breakout After Long Downtrend 📈🔥
Tatva Chintan Pharma has broken a multi-year falling trendline, ending a prolonged downtrend phase since 2021.
This breakout is backed by strong price momentum + volume expansion, indicating accumulation and potential reversal into a long-term uptrend.
📌 Breakout Zone: ~₹1350 – ₹1400
📌 Current Price: ~₹1467
📌 Structure: Breakout + retest + continuation
📌 Momentum: Trading above 50 & 200 EMA on weekly 👌
Key Levels
Immediate Resistance:
Support Zones
As long as price sustains above ₹1310-1340 range, bullish structure remains intact ✅
Why This Breakout Matters
✅ Multi-year trendline breach
✅ Higher-lows forming since 2024 bottom
✅ Strong accumulation volume
✅ Pharma sector strength visible
✅ Potential trend reversal from long accumulation base
This kind of pattern often leads to multi-month swing opportunities if trend sustains.
View
Bias remains bullish until structure breaks.
Watching for follow-through above ₹1500 zone for extended upside.
📒 Educational chart analysis — not investment advice.
Tatva Chintan Pharma has broken a multi-year falling trendline, ending a prolonged downtrend phase since 2021.
This breakout is backed by strong price momentum + volume expansion, indicating accumulation and potential reversal into a long-term uptrend.
📌 Breakout Zone: ~₹1350 – ₹1400
📌 Current Price: ~₹1467
📌 Structure: Breakout + retest + continuation
📌 Momentum: Trading above 50 & 200 EMA on weekly 👌
Key Levels
Immediate Resistance:
- ₹1468 (current zone)
- ₹1594
Support Zones
- ₹1395
- ₹1343
- ₹1311 (major retest zone)
As long as price sustains above ₹1310-1340 range, bullish structure remains intact ✅
Why This Breakout Matters
✅ Multi-year trendline breach
✅ Higher-lows forming since 2024 bottom
✅ Strong accumulation volume
✅ Pharma sector strength visible
✅ Potential trend reversal from long accumulation base
This kind of pattern often leads to multi-month swing opportunities if trend sustains.
View
Bias remains bullish until structure breaks.
Watching for follow-through above ₹1500 zone for extended upside.
📒 Educational chart analysis — not investment advice.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
